Desh Bandhu Gupta
Founded in 1968, Lupin had its humble roots in one man’s dream of creating a better world for everyone. Desh Bandhu Gupta or “DBG” as he was fondly known as, believed in the idea of simple living and high thinking and aspired to put India on the global pharmaceutical map. With the rich heritage we have built over the past 53 years, Lupin is today one of the leading pharmaceutical companies in India. Our global footprint spans over a hundred countries and we have world-class operations with a powerful culture of innovation and unyielding integrity.
The name ‘Lupin’ was inspired by the flower of the same name, which is known to thrive despite infertile soil and is capable of nurturing change. These qualities form the foundation of the company’s ethos as we passionately strive to provide accessible and affordable healthcare solutions to patients across the globe.
Headquartered in Mumbai, India, our position as a fully integrated pharmaceutical company is built on the backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. We are confident that these building blocks will help us meet the most pressing demands in healthcare, and help create a better tomorrow.
We are a truly multinational pharmaceutical company focused on a meaningful and diverse product portfolio, comprising Generics, Biosimilars, and Specialty Products. Lupin manufactures and markets an extensive variety of branded and generic formulations, Active Pharmaceutical Ingredients (APIs), biotechnology products as well as Over-the-Counter (OTC) medicines across multiple dosage forms and therapeutic categories. In addition, we are acknowledged as one of the largest manufacturers of anti- Tuberculosis drugs in the world and are proud of our global leadership position in areas such as Anti- TB and Cephalosporins.
With over 15 state-of-the-art manufacturing facilities spread across India, the United States, Brazil and Mexico and a workforce of over 20,000 personnel committed to enhancing the quality of our patients’ lives, we are working towards expanding access to newer and innovative healthcare solutions at scale.
We will continue to enhance our leadership by introducing new drugs and adding more therapies, with a sharp focus on India and the US.
• We continue to target Loss of Exclusivity (LOE) opportunities in the US as well as increase our presence in non-solid oral dosage forms such as inhalation, injectables, ophthalmic, and dermatological products
• Forming strategic alliances and in-licensing is a critical strategy to widen our product offering and drive growth, especially in India, where we continue to maintain our thrust on chronic therapies (more than 65% of our revenues)
• We are expanding our offering within the Gynaecology, Dermatology, Urology, and Paediatrics therapy segments in India
• For our established and stable businesses in South Africa, Brazil, Mexico and Australia, our goal is to exceed industry growth and sustain profitability through new launches and cost optimization
For other developing markets, our strategy is to drive them towards a self-sustainable path of profitability and growth.
Successfully executing on our Complex Generics pipeline is critical to ensure that we continue to improve our profits as well as bring more sustainability to the business. We have three focus areas for Complex Generics - Inhalation, Biosimilars and Complex Injectables. Specific to these areas, we have built a strong pipeline and will continue to focus on delivering on this pipeline.
• Inhalation: We are one of the few companies in the world to have filed a Dry Powder Inhaler as well as a Metered Dose Inhaler in the US. We have to date filed five major inhalation products in the US (generics to ProAir®, Spiriva® , Dulera®, Perforomist® and Brovana®, addressing US sales of almost USD 4.7 billion IQVIA MAT March 2021
• Biosimilars: We filed our first biosimilar Etanercept (global sales of approximately USD 10.3 billion, IQVIA MAT March 2021) in Japan and Europe, a key milestone in our biosimilars journey
• In FY19, we partnered with Mylan and Nichilko for commercializing Nepexto® (biosimilar Etanercept) in Europe and Japan respectively
We are focused on building specific Specialties in select advanced markets:
• Zaxine®, sold in Canada, focuses on the Gastrointestinal Therapy and is the largest Specialty brand promoted by Lupin. The brand showed 9% growth in FY21 despite COVID-19 driven challenges. The plan is to accelerate the growth of Zaxine® through marketing efforts focused on primary care physicians
• Solosec®, our lead Women’s Health product in the US was launched in May 2018. We continue to look at potential inorganic opportunities and distribution partnerships to add more products and leverage this platform
• On the CNS front, our focus is on Neurology, with our orphan drug NaMuscla® launched in the UK, Germany, France and in several other European countries
In FY20, Lupin initiated a transformational journey to streamline our business strategy for growth and help us build an industry-best cost position.
• Our aim is to improve the efficiency and productivity of our R&D function in activities such as development, filing, approval and launching of products, and building agility in the supply chain
• On the operational front, we continue to drive procurement efficiencies and improvement through a focus on optimizing our cost base and creating Centres of Excellence for support services
Compliance to applicable regulatory standards is a key priority and we adhere to the highest standards of quality. Our facilities across the globe observe Good Manufacturing Practice (GMP) standards and have accreditations from leading global regulatory authorities such as USFDA, UK MHRA, WHO and Japanese PMDA.